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Randomized clinical trials (RCTs) have had a pivotal role 
in supporting advances in inflammatory bowel disease 
(IBD) care. However, concerns are growing surround-
ing the ability to deliver future trials in IBD. The rising 
number of investigational agents undergoing late- phase 
assessment has increased the demand for trial partici-
pants. Conversely, the increased availability of licensed 
treatments has reduced clinical equipoise and reduced 
the incentive for trial participation. Increasingly rigor-
ous trial schedules have also increased the burden of 
trial participation. The globally declining recruitment 
rates to IBD trials predates the coronavirus disease 2019 
(COVID-19) pandemic1,2, but concerns about declin-
ing recruitment rates have been magnified during this 
event. These concerns have resulted in calls to modify 
the conduct of trials in IBD in order to make them more 
efficient and patient centred3.
During the COVID-19 pandemic, IBD trial activity 
has reduced majorly, even across sites with historically 
high levels of research involvement4. In response, sug-
gestions were made for modifications to trials including 
considerations for remote visits, possible alternatives 
to endoscopic investigation and strategies to minimize 
steroid exposure. Although these modifications were 
proposed to be temporary, they might also offer some 
longer- term solutions to the ongoing difficulties of 
IBD trials5.
Informed consent is a critical process in RCTs and 
has typically occurred during face- to- face clinical visits. 
This practice reflects existing regulatory requirements 
for handwritten, dated and signed consent forms, as well 
as physician and patient familiarity with counselling 
during an in- person visit. During the COVID-19 pande-
mic, clinicians have become increasingly familiar with 
remote consultation and, at the same time, trial spon-
sors have had to consider the possibility of electronic 
consent (e- consent). This change has been associated 
with high levels of participant satisfaction, particularly 
when user- friendly interfaces are used and where parti-
cipant requirements are clearly presented. The benefits 
of e- consenting also include widening access and oppor-
tunities to more individuals, including those living in 
remote settings and those who have difficulty attending 
clinic visits. The merits of e- consenting, however, will 
need to be considered on a trial- by- trial basis, and it 
will be appropriate for the consent process of RCTs to 
retain the opportunity for patients to have a detailed dis-
cussion with physicians. Nevertheless, we suggest that 
these discussions are possible within a remote consul-
tation, affording the opportunity to reflect on treatment 
schedules and potential risks without the inconvenience 
(and perhaps indirect pressure) of an in- person visit.
Historically, when few treatments were available for 
IBD, the demand for more effective interventions was 
clear and trial participants were regarded as the ‘lucky 
few’. Nowadays, with a growing number of licensed 
treatment options, it has become increasingly important 
to consider the convenience of therapies as well. Indeed, 
patient preferences have been highlighted as one of the 
key drivers behind subcutaneous and oral drug devel-
opment programmes. Additionally, research has now 
shown that patients are more likely to participate in 
RCTs that have limited or no placebo interventions and 
where there is also a possibility of open- label extension 
to active treatments6. For both ethical and scientific rea-
sons, we feel that sponsors should consider trial designs 
with active comparator arms alongside new treatments.
Again, the COVID-19 pandemic has accelerated a 
global shift towards telemedicine and virtual health- care 
provision. This change has caused some apprehension 
among sponsors, as many trial schedules have histori-
cally mandated face- to- face assessments to ensure 
accuracy of data collection. Nonetheless, evidence from 
the pandemic has shown that it is possible to conduct 
predominantly virtual consultations and still ensure 
accurate, remote data collection4.
A key criticism of many current IBD trial schedules is 
that they are overly burdensome for patients, resulting in 
negative effects on both recruitment and retention. In this 
regard, we advise early engagement with patient and 
public involvement representatives, to improve patient 
acceptability of trial designs. In particular, the collec-
tion of biological samples and monitoring of biological 
parameters has previously been seen as a necessity for 
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patients to attend hospital clinics. However, technolo-
gies to enable home testing for blood and stool samples, 
used alongside results extracted from routinely collected 
health data (RCHD), offer substantial promise and the 
opportunity for change. Although the concept of using 
RCHD for RCT follow- up might seem unrealistic given 
the many challenges surrounding data access, evidence 
is increasing that these challenges can be overcome7, and 
we believe that integrating systems to allow the use of 
RCHD should be a priority area of focus in the field.
Patient- reported outcome measures are increasingly 
being used for RCTs in IBD. Alongside patient- reported 
outcome measures, endoscopic assessment has emerged 
as a critical objective end point, given the increasing 
evidence of association with longer- term outcomes8. 
Conversely, patients with IBD have consistently identi-
fied that the need for endoscopy, and especially the need 
for multiple endoscopies, is a factor that would decrease 
their likelihood of participation in research6,9. This 
challenge is a difficult one to overcome and we note 
the recent SPIRIT consensus recommendations, which 
suggest that noninvasive measures might be considered 
an appropriate, future, objective end point in IBD10. 
Despite widespread acknowledgement for the benefits 
of noninvasive tests such as faecal calprotectin, ultra-
sound or MRI, these measures are not recognized by 
regulators as suitable end points for registration of trials 
owing to a lack of validation. Even in early- phase trials, 
the precedent for using these modalities as a primary 
outcome measure is limited. A crucial aspect for pro-
gression in the field will be to generate validated, quan-
titative data from noninvasive modalities correlating 
with endoscopic findings, such that these noninvasive 
targets could be adopted as co- primary end points in 
future trials.
The number of potential therapeutic options for IBD 
is growing, and RCTs remain the gold- standard method 
of assessment for efficacy and safety. However, there is 
an increasing recognition that IBD trials need to become 
more patient centred, and we have proposed a number 
of potential modifications. For some of these, such as 
e-consenting and remote data collection, the techno-
logy and infrastructure is already well developed, and 
what is required is a shift in the stance of sponsors. Other 
changes, such as the increased use of active comparators, 
will require greater shifts away from traditional trial 
designs but are absolutely deliverable. Further devel-
opment of noninvasive end points to satisfy regulators 
will require considerable effort, but should be an area of 
priority in this next era of improvement for RCTs in IBD.
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